Estrella Immunopharma grants CEO 1M stock options

The grant's staged vesting begins October 25, 2027, and each vesting date is subject to continued service.

Available on EDGAR 11/04/2026 - 07:23 AM EST Accepted by SEC EDGAR 11/04/2026 - 07:23 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Estrella Immunopharma, Inc. CEO Cynthia Pussinen was granted options covering 1,000,000 common shares, with an exercise price of $0.43 per share. The options vest as to 25% on October 25, 2027, and the remaining 75% in 36 substantially equal monthly installments thereafter, subject to continued service through each vesting date. They expire November 2, 2036 and were granted under the 2023 Omnibus Incentive Plan, with advance approval by the Compensation Committee and Board of Directors in accordance with Rule 16b-3(d).

Insider Trade Summary

Grant/Award: 1,000,000 shares

Grant/Award 1 txn

Insider Pussinen Cynthia

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2, F1	1,000,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,000,000 contracts (Direct)

Footnotes (2)

1. F1. The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer through each vesting date.
2. F2. The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d).

Key Figures

Options granted: 1,000,000 options Exercise price: $0.43 per share Initial vesting: 25% +3 more

6 metrics

Options granted 1,000,000 options Direct grant to CEO Cynthia Pussinen

Exercise price $0.43 per share Option grant

Initial vesting 25% Vests on October 25, 2027

Remaining vesting 75% Vests in 36 substantially equal monthly installments thereafter

Vesting installments 36 substantially equal monthly installments For the remaining 75% of the underlying shares

Option expiration November 2, 2036 Expiration date

Key Terms

exercise price, substantially equal monthly installments, 2023 Omnibus Incentive Plan, Rule 16b-3(d)

4 terms

exercise price financial

"with an exercise price of $0.43 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

substantially equal monthly installments technical

"in 36 substantially equal monthly installments thereafter"

2023 Omnibus Incentive Plan technical

"granted under the Issuer's 2023 Omnibus Incentive Plan"

Rule 16b-3(d) regulatory

"in accordance with Rule 16b-3(d)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Was Cynthia Pussinen's ESLA option grant approved?

Yes. The options were granted under Estrella Immunopharma's 2023 Omnibus Incentive Plan and were approved in advance by the Compensation Committee and Board of Directors in accordance with Rule 16b-3(d).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pussinen Cynthia

(Last) (First) (Middle)

5858 HORTON ST, SUITE 370

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Estrella Immunopharma, Inc. [ ESLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.43	11/02/2026		A(2)		1,000,000		(1)	11/02/2036	Common Stock	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 25% of the underlying shares on October 25, 2027 and as to the remaining 75% in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer through each vesting date.

2. The option was granted under the Issuer's 2023 Omnibus Incentive Plan and was approved in advance by the Compensation Committee of the Board of Directors and the Board of Directors in accordance with Rule 16b-3(d).

	Cynthia Pussinen	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)